High Tone Pelvic Floor Dysfunction

Status Completed

Clinical Trial Summary

Dyspareunia, or painful intercourse, is one of the most commonly reported complaints in postmenopausal women. One common cause of dyspareunia is vaginal atrophy (VVA), which occurs in >50% of postmenopausal women. At the time of menopause, a lack of estrogen thins the vaginal mucosa and lessons lubrication, making sex painful. Some women with vaginal atrophy will also have high tone pelvic floor dysfunction (HTPFD) (also known as levator spasm). Successful treatment of the sexual pain requires treatment of both vaginal atrophy and HTPFD.

How often vaginal atrophy and HTPFD coexist has not been studied. In fact, the prevalence of HTPFD is unknown. This is most likely due to the fact that many clinicians are unaware of its existence or how to diagnose or treat it. Also, sexual symptoms tend to be underreported due to embarrassment or hesitation to seek care. HTPFD frequently coexists with other conditions that cause pain like vaginal atrophy, endometriosis or interstitial cystitis. Treatment includes treating both conditions. If only one is treated, then sexual pain is likely to continue. There are several available treatments for HTPFD that have been studied including physical therapy, botox and intravaginal diazepam.

This is an area where clinicians may be under treating a condition and limiting the possibility of restoring normal sexual function to many women. Treating only vaginal atrophy without appropriate evaluation and treatment of HTPFD leaves a cohort of women still struggling with sexual pain. With a better understanding of the relationship between HTPFD and vaginal atrophy, the investigators hope to bring awareness concerning the importance of treating both in restoring normal sexual function.

Clinical Trial Description

This is a retrospective chart review that will be performed to identify all female patients in the electronic medical records with a diagnosis of vulvovaginal atrophy (VVA).

The records of these patients with VVA will be examined for demographics, symptoms, answers to standardized questionnaires ( e.g. Female Sexual Function Index - FSFI - that is routinely assessed during clinical evaluation), work-up, diagnosis, and/or treatment of high tone pelvic floor dysfunction (HTPFD). Symptoms of HTPFD include but are not limited to pelvic pressure or pain, and dyspareunia. These data will then undergo statistical analysis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03083262
Study type	Observational
Source	St. Louis University
Contact
Status	Completed
Phase	N/A
Start date	January 31, 2017
Completion date	February 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04210583` - RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity	N/A
Completed	`NCT03725410` - Multi-polar RF and PEMF for Treatment of Symptoms Associated With Vulvovaginal Atrophy	N/A
Recruiting	`NCT03823560` - Performance and Safety of Class IIb MD Celegyn® in VVA	N/A
Completed	`NCT02253173` - Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women	Phase 3
Withdrawn	`NCT03666819` - Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy	Phase 2
Recruiting	`NCT04746456` - Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM
Completed	`NCT04607798` - Multi-polar RF and PEMF for Treatment of Vulvovaginal Atrophy	N/A
Completed	`NCT04766957` - Pilot Clinical Trial of IDRACARE® in Moderate to Severe Symptoms of Vulvovaginal Atrophy	N/A
Completed	`NCT01455597` - Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)	Phase 3
Completed	`NCT03557398` - Efficacy and Safety of HYDEAL-D Vaginal Pessaries Application on the Treatment of Vaginal Atrophy in Post-menopause Women	N/A
Completed	`NCT03044652` - Investigation of Non-inferiority of Treatment of Vulvovaginal Dryness With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol	Phase 4
Completed	`NCT03536585` - Multi-polar RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity	N/A
Completed	`NCT04629885` - Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms	Phase 2
Recruiting	`NCT04579991` - Effects of Visnadin, Ethyl Ximeninate, Coleus Barbatus and Millet in Emulgel on Sexual Function in Postmenopausal Women	N/A
Recruiting	`NCT05562518` - GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.	Phase 4
Completed	`NCT02419729` - Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy	Phase 3
Completed	`NCT02085980` - Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy	N/A
Completed	`NCT01319968` - Postpartum Dyspareunia Resulting From Vaginal Atrophy	N/A
Recruiting	`NCT03782480` - Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy	Phase 3
Completed	`NCT04887701` - Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women	N/A